Citations

Clear

9383 citation(s) found for "Thomas, PS".

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
Bock, Allison M. , Wenzl, Kerstin , Stokes, Matthew E. , Hopper, Melissa A. , Dropik, Abigail R. , Sarangi, Vivek, Ortiz, Maria, Huang, Chuican , King, Rebecca L., Ansell, Stephen M., Gandhi, Anita K. , Nowakowski, Grzegorz S. , Novak, Anne J. , Hopper, Melissa A , Dropik, Abigail R , Wang, Yucai , Witzig, T.E. , Novak, Joseph P. , Krull, Jordan E. , Stong, Nicholas , Maurer, Matthew J. , Farooq, Umar , Wang, Yucai , Witzig, Thomas E. , Ansell, Stephen M. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

Hematological Oncology | November 29, 2024 | Volume: 43 | Issue: 1 | Pages: No page available

10.1002/hon.70006 | PMID 39612356 Get It

ABSTRACTDiffuse large B‐cell lymphoma (DLBCL) patients that fail to achieve a complete metabolic response with frontline immunochemotherapy have a poor prognosis. Genomic profiling has led to a broader understanding of the molecular drivers in DLBCL, but it is unknown how well current classifiers identify patients that will experience primary treatment resistance (PTR). Using whole exome and RNA sequencing data from newly diagnosed DLBCL patients, we evaluated the genomic landscape of PTR and compared it to that of non‐PTR DLBCL. We found a significant increase in the frequency of TP53 (34% vs. 15%, p = 0.005) and ARID1A mutations (21% vs. 7%, p = 0.007) in PTR cases, with pathway analysis further demonstrating a downregulation of TP53 and an increase in chromatin modifying pathways. These results suggest that TP53 and ARID1A may be key mediators of PTR and important pathways contributing to the poor outcomes. We found that the current molecular classifiers were unable to identify PTR cases at diagnosis. However, our newly identified high‐risk signature identified 46% of PTR cases at diagnosis. Overall, these results contribute to our understanding of the genomic landscape of patients with primary treatment resistance.
Integrating patient advocacy groups in the development of clinical practice guidelines: comment on the article by Johnson et al
Carsons, Steven E. , Carteron, Nancy , Scofield, R. Hal , Lee, Augustine S. , Thomas, Donald E. , Moua, Teng , Clair, E. William St. , Meehan, Richard T. , Dunleavy, Kieron , Makara, Matt, Hammitt, Katherine M. , Meehan, Richard , Hammitt, Katherine Morland , Dunleavy, Kieron , Gupta, Nishant , Thomas, Donald E., Ussavarungsi, Kamonpun

Mayo Clinic

Arthritis Care & Research | November 28, 2024 | Volume: 77 | Issue: 5 | Pages: 685-686

10.1002/acr.25474 | PMID 39605233 Get It

Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium
Day, Jonathan R , Koff, Jean L. , Wang, Yucai , Lossos, Izidore S. , Nastoupil, Loretta J. , Strouse, Christopher , Chihara, Dai , Martin, Peter , Leonard, John P. , Cohen, Jonathon B. , Ruan, Jia , Friedberg, Jonathan W. , Flowers, Christopher R. , Koff, Jean L , Wang, Yucai , Lossos, Izidore S , Nastoupil, Loretta J , Chihara, Dai , Cohen, Jonathon B , Kahl, Brad S , Burack, W Richard , Cerhan, James R , Link, Brian K , Maurer, Matthew , Casulo, Carla , Strouse, Christopher S , Larson, Melissa C. , Durani, Urshila , Habermann, Thomas M. , Martin, Peter, Kahl, Brad S. , Burack, Richard , Cerhan, James R. , Link, Brian K. , Maurer, Matthew J. , Casulo, Carla

Mayo Clinic

Blood Advances | November 27, 2024 | Volume: 9 | Issue: 5 | Pages: 1013-1023

10.1182/bloodadvances.2024014053 | PMID 39602301 Get It

Abstract Progression of disease within 24 months of initial immunochemotherapy (POD24) is a negative prognostic factor for patients with follicular lymphoma (FL). There is no standard treatment after POD24. Assembling an academic-based cohort from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence, we evaluated patterns of care and outcomes for 220 patients with FL with POD24 and retained FL histology. Therapy after POD24 was heterogeneous, with no treatment category accounting for >25% of the total. Among patients initially treated with bendamustine-rituximab, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) was the predominant second-line choice (48%). Among patients initially treated with R-CHOP, aggressive salvage therapy was the predominant second-line choice (38%). Overall response rate to therapy after POD24 was 64% (95% confidence interval [CI], 56-70); complete response rate was 39% (95% CI, 32-46). The median event-free survival for therapy after POD24 was 9.8 months (95% CI, 7.3-12.1); 5-year overall survival (OS) was 71% (95% CI, 65-78). OS was inferior for patients aged >70 years (hazard ratio [HR], 2.31; 95% CI, 1.27-4.20) and those with high-risk FL International Prognostic Index scores at diagnosis (HR, 2.10; 95% CI, 1.23-3.60). No treatment category stood out with more favorable results. Cause of death was predominantly lymphoma related. Patients with follicular histology at their POD24 event had a low cumulative incidence of transformation (1.1% at 5 years). Our study is among the largest cohorts describing contemporary patterns of care for patients with POD24, providing a focused data set useful for interpreting and designing prospective clinical trials in this population.
Society of Radiologists in Ultrasound response to ‘Proposed simplified protocol for initial assessment of endometriosis with transvaginal ultrasound’
Young, Scott W. , VanBuren, W., Kho, Rosanne M. , Groszmann, Yvette S. , Feldman, Myra , Khan, Zaraq , Young, S. L., Endometriosis, the Society of Radiologists in Ultrasound Consensus Panel on Routine Pelvic Ultrasound for, Young, Scott W , Jha, Priyanka , Rodgers, Shuchi K. , Burnett, Tatnai L. , Chamié, Luciana Pardini , Horrow, Mindy M. , Young, S. L., Young, Steven L. , Endometriosis, the Society of Radiologists in Ultrasound Consensus Panel on Routine Pelvic Ultrasound for

Mayo Clinic

Ultrasound in Obstetrics & Gynecology | November 27, 2024 | Volume: 65 | Issue: 2 | Pages: 243-245

10.1002/uog.29147 | PMID 39601344 Get It

Linked article: This Correspondence comments on Deslandes and Leonardi. Click here to view the article.
Factors Influencing Nasoalveolar Molding Treatment Completion and Noncompletion in Infants with Cleft Lip and Palate
Herrman, Elisa, Dierkhising, Ross , Lee, Sarah K. , Salinas, Thomas , Sarvas, Elise , Viozzi, Christopher F. , Muller, Olivia M. , Herrman, Elisa I , Sarvas, Elise W

Mayo Clinic

The Cleft Palate Craniofacial Journal | November 26, 2024 | Volume: 62 | Issue: 2 | Pages: 214-222

10.1177/10556656241293682 | PMID 39588572 Get It

Objective Identify sociodemographic factors and comorbidities predictive of nasoalveolar molding (NAM) treatment completion and noncompletion in infants with cleft lip with or without (+/–) cleft palate in a rural-suburban population. Design Retrospective cohort study. Setting Tertiary medical center. Patients, Participants Infants diagnosed with cleft lip +/- cleft palate who initiated NAM treatment between 2013 and 2023. Forty-seven patients met inclusion criteria. Main Outcome Measure(s) Prevalence of NAM treatment completion, defined as continued attendance of NAM appointments until initial lip repair surgery. Results NAM treatment noncompletion rate of 23.4%. Noncomplete NAM treatment was associated with greater additional unscheduled NAM visits ( P < .001); increased days inpatient after birth ( P < .001); NICU admission ( P < .001); public insurance ( P = .007); preterm birth ( P = .008); history of social work visits ( P = .024); increased comorbidities ( P = .028); non-Caucasian race ( P = .034); and presence of siblings ( P = .036). Associated comorbidities included use of feeding tube ( P < .001); and conditions related with renal ( P < .001); cardiac ( P = .004); failure to thrive ( P = .009); syndromes ( P = .009); orthopedic ( P = .011); pulmonary ( P = .022); and ophthalmologic systems ( P = .041). Conclusions Increased overall health complexity, public insurance status, and need for social work support were identified as factors associated with NAM noncompletion. These variables can help identify patients at risk of noncompletion and empower providers to supply individualized support and resources.
ST-Segment Elevation in the Stress Laboratory
Galeano-Lovera, Santiago F. , Kusumoto, Fred, Allison, Thomas G. , Kusumoto, Fred

Mayo Clinic

JAMA Internal Medicine | November 25, 2024 | Volume: 185 | Issue: 1 | Pages: 101

10.1001/jamainternmed.2024.2890 | PMID 39585669 Get It

This case report describes a woman in her early 60s who went into cardiac arrest immediately after administration of an echocardiogram contrast agent.
Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance
Ganti, Apar Kishor , Fruth, Briant, Mix, M. , Petty, W. Jeffrey , Stinchcombe, Thomas E. , Bogart, Jeffrey A. , Dueck, Amylou C., Dueck, Amylou C. , Dueck, A. C. , Ganti, Apar K , Stinchcombe, Thomas E , Rimner, Andreas , Waqar, Saiama N , Vokes, Everett E.

Mayo Clinic

Cancer | November 24, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35663 | PMID 39580636 Get It

AbstractBackgroundCALGB 30610 trial demonstrated that once daily thoracic radiotherapy (TRT) was not superior compared to standard twice daily TRT, in patients with limited stage small cell lung cancer. Quality of life outcomes may help oncologists decide the best treatment approach.MethodsA total of 417 patients on CALGB 30610 participated in the quality‐of‐life substudy (CALGB 70702), which included the FACT Trial Outcome Index‐Lung Cancer (FACT‐L TOI), FACT‐Esophageal Cancer (FACT‐E) Eating and Swallowing Indices, ECOG Acute Esophagitis Scale, Hospital Anxiety and Depression Scale (HADS), difficulty swallowing, EQ‐5D, and treatment convenience assessment at baseline, 3, 5, 7, 12, 26, and 52 weeks after starting TRT. Primary end points included FACT‐L TOI and FACT‐E at 12 weeks. Mean changes from baseline were compared between arms using general linear mixed models.ResultsFACT‐L worsening was more in the twice daily arm at week 3 (–1.0 vs. –7.0). FACT‐L TOI worsening was less at week 3 (–2.9 vs. –7.6) and greater at week 12 (–7.6 vs. –2.8) in the once daily arm. The once daily arm had a lower EQ‐5D index worsening at 3 weeks (0.01 vs. –0.02). Increase in acute esophagitis score (1.06 vs. 2.89; p < .001) and difficulty swallowing (0.39 vs. 1.14) were greater in the twice daily arm at week 3. A total of 74.5% of patients on the once daily arm felt that treatment was convenient, compared to 67% of patients in the twice daily arm (p = .03).ConclusionsThe once daily arm had better quality‐of‐life scores earlier during treatment and was perceived to be more convenient.
Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations
Smith, Katherine E. , Dasari, Surendra , Ranatunga, Wasantha , Rech, Karen L. , Ravindran, Aishwarya , McGarrah, Patrick W. , Ruan, Gordon , Zanwar, Saurabh , Sartori‐Valinotti, Julio C. , Snider, Jessica N., Abeykoon, Jithma P. , Smith, Katherine E R , Acosta-Medina, Aldo A, Rech, Karen , McGarrah, Patrick , Ruan, Gordon J , Zanwar, Saurabh S , LI, JENNY J., Sartori-Valinotti, Julio C., Witzig, T.E. , Goyal, Guarav , Go, Ronald S , Abeykoon, Jithma P , Ravindran, Aishwarya , Acosta‐Medina, Aldo A. , Young, Jason R. , Li, Jing , Witzig, Thomas E. , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

JCO Precision Oncology | November 22, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po-24-00471 | PMID 39576953 Get It

PURPOSE BRAF and MEK inhibitors are standard treatments in histiocytic disorders, such as Erdheim-Chester disease (ECD). Some patients lack MAPK-pathway alterations, making these treatments less effective. METHODS We describe three patients with histiocytic disorders who have novel non-MAPK pathway alterations. These alterations were studied through genomic and in silico analyses when applicable, then treated with off-label medications rationally selected on the basis of genomic alterations. RESULTS Patient 1 had rapidly progressive ECD involving the CNS. A CSF1R in-frame deletion (p.S560_P566del) was identified, and in silico modeling predicted a gain-of-function mutation. This alteration was targeted with pexidartinib, which led to a clinical complete response (CR) within 2 months, and a partial response (PR) on imaging after 3 months. After 15 months, the disease became resistant to pexidartinib and transformed to histiocytic sarcoma. Patient 2 has skin-only involvement of a xanthogranuloma disorder. A KIF5B-FGFR1 fusion was identified on RNA sequencing and targeted with pemigatinib. At 24 months of follow-up, she remains in a clinical PR. Patient 3 has ECD involving the bone marrow, gastrointestinal tract, and subcutaneous tissues. A MEF2C-FLT3 fusion was identified and targeted with sorafenib. He achieved a clinical CR and radiographic PR within 3 months, which has continued for 30 months. CONCLUSION We report three patients with histiocytic disorders harboring novel alterations who had sustained responses to off-label kinase inhibitors specific to their histiocytic disorder. Pathogenic variants outside of the MAPK pathway, including variants of unknown significant, may be targeted with readily available small molecules.
Practice Advisory on the Implementation of Preoperative Anemia Management: The Society of Cardiovascular Anesthesiologists and the Society for the Advancement of Patient Blood Management
Burt, Jennifer M., Grant, Michael C. , Guinn, Nicole R. , Patel, Prakash A. , Popescu, Wanda M. , Raphael, Jacob , Salenger, Rawn , Shore‐Lesserson, Linda , Klompas, Allan M. , Hensley, Nadia B. , Warner, Matthew A.

Mayo Clinic

Anesthesia & Analgesia | November 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1213/ane.0000000000007321 | PMID 39671507 Get It

Preoperative anemia is common and associated with worse outcomes in cardiac surgery including acute kidney injury, red blood cell transfusion, cardiovascular complications, stroke, infection, and death. Patient blood management programs, which include dedicated clinical programs to diagnose and treat anemia in advance of surgery (ie, preoperative anemia programs), have been highlighted as a means to optimize the blood health of each patient, thereby decreasing risk for allogeneic transfusion and improving clinical outcomes. However, there remain implementation challenges for preoperative anemia programs, including difficulties with education of patients and staff, short lead times to address anemia, infrastructure and staffing limitations, lack of clear leadership or ownership of preoperative anemia, the need to develop treatment algorithms and ensure appropriate infusion therapy support, lack of capital support, and insurance/reimbursement concerns, amongst others. The purpose of this advisory from the Society of Cardiovascular Anesthesiologists (SCA) Clinical Practice Improvement Committee and the Subcommittee on Patient Blood Management with endorsement from the Society for the Advancement of Patient Blood Management (SABM) is to provide guidance on the development and implementation of a preoperative anemia clinic or service line, including identification and navigation through potential logistical barriers. A detailed analysis of financial incentives is highlighted in our companion article in this edition focuses on the return on investment of anemia management. Although originating with a focus on anemia before cardiac surgery, this advisory is broadly applicable to all perioperative patients.
OPTIMIZING PERIPROSTHETIC JOINT INFECTION DIAGNOSTICS: THE IMPACT OF INTRAOPERATIVE DIRECT SONICATION ON TIME TO POSITIVITY
Xu, Boyong , Li, Yicheng , Zhang, Xiaogang , Cao, Li , Mu, Wenbo , Tarabichi, Saad , Wang, Fei , Lizcano, Juan D , Parvizi, Javad

Mayo Clinic

Orthopaedic Proceedings | November 22, 2024 | Volume: 106-B | Issue: SUPP_19 | Pages: 42-42

10.1302/1358-992x.2024.19.042 Get It

AimThis study aimed to evaluate the impact of intraoperative direct sonication on the yield of traditional culture and the time to positivity (TTP) of cultures obtained for periprosthetic joint infection (PJI), thereby assessing its potential to improve diagnostic efficiency and reduce contamination risk.MethodA prospective cohort study was conducted at a tertiary care center, involving 190 patients undergoing revision surgery for PJI from August 2021 to January 2024. Patients were included based on the 2018 International Consensus Meeting definition of PJI. The study utilized a novel sonication protocol, which involved direct intraoperative sonication of the implant and tissue, followed by incubation in a BACT/ALERT 3D system. The primary outcomes measured were the number and percentage of positive culture samples, identified microorganisms, and the TTP of each culture. Statistical analysis was performed using R software, with various tests applied to assess the significance of findings.ResultsThe study included 510 positive cultures from 190 patients, demonstrating that sonication significantly improved the positivity rate for both tissue and prosthesis specimens (p < 0.05). The median TTP for all samples was 3.13 days, with sonicated samples showing a significantly shorter TTP compared to non-sonicated samples (p < 0.05). Specifically, the shortest median TTP was observed in prosthesis post-sonication samples. Furthermore, the study found that Gram-positive organisms had a shorter TTP than gram-negative organisms, and specific microorganisms like Staphylococcus aureus and MRSE showed the fastest TTP. The analysis also revealed higher positivity rates in chronic PJIs compared to acute PJIs for sonicated tissue samples.ConclusionsThe study demonstrates that intraoperative direct sonication combined with the BACT/ALERT 3D system can significantly enhance the diagnostic yield of cultures and reduce the TTP for common PJI pathogens. This novel technique not only improves pathogen detection, facilitating the tailoring of antibiotic therapy, but also potentially reduces the risk of contamination associated with sonication. These findings suggest that direct intraoperative sonication could be a valuable addition to the current diagnostic protocols for PJI, contributing to more effective management and treatment of this complex condition. Further research is necessary to explore the clinical significance of TTP and its correlation with patient outcomes in PJI.